tetano
Editor, Senior Moderator
J Infect Dis
. 2024 Mar 5:jiae072.
doi: 10.1093/infdis/jiae072. Online ahead of print. A Novel Anti-nucleocapsid Antibody Avidity Method for Identifying SARS-CoV-2 Reinfections
Liam Golding[SUP] 1 2 [/SUP], Allison W Watts[SUP] 1 [/SUP], Jacob Shew[SUP] 1 2 [/SUP], Marina Viñeta Paramo[SUP] 1 2 3 [/SUP], Louise C Mâsse[SUP] 1 4 [/SUP], David M Goldfarb[SUP] 1 5 [/SUP], Bahaa Abu-Raya[SUP] 1 2 [/SUP], Pascal M Lavoie[SUP] 1 2 3 [/SUP]
Affiliations
Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections is challenging with current serology assays and is further complicated by the marked decrease in routine viral testing practices as viral transmission increased during Omicron. Here, we provide proof-of-principle that high-avidity anti-nucleocapsid (N) antibodies detects reinfections after a single infection with higher specificity (85%; 95% confidence interval [95% CI], 80%-90%) compared to anti-N antibody levels (72%; 95% CI, 66%-79%) in a vaccinated cohort. This method could be used to retroactively investigate the epidemiology and incremental long-term health consequences of SARS-CoV-2 reinfections.
Keywords: COVID-19; SARS-CoV-2; avidity; nucleocapsid; reinfection; serology.
. 2024 Mar 5:jiae072.
doi: 10.1093/infdis/jiae072. Online ahead of print. A Novel Anti-nucleocapsid Antibody Avidity Method for Identifying SARS-CoV-2 Reinfections
Liam Golding[SUP] 1 2 [/SUP], Allison W Watts[SUP] 1 [/SUP], Jacob Shew[SUP] 1 2 [/SUP], Marina Viñeta Paramo[SUP] 1 2 3 [/SUP], Louise C Mâsse[SUP] 1 4 [/SUP], David M Goldfarb[SUP] 1 5 [/SUP], Bahaa Abu-Raya[SUP] 1 2 [/SUP], Pascal M Lavoie[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 38442331
- DOI: 10.1093/infdis/jiae072
Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections is challenging with current serology assays and is further complicated by the marked decrease in routine viral testing practices as viral transmission increased during Omicron. Here, we provide proof-of-principle that high-avidity anti-nucleocapsid (N) antibodies detects reinfections after a single infection with higher specificity (85%; 95% confidence interval [95% CI], 80%-90%) compared to anti-N antibody levels (72%; 95% CI, 66%-79%) in a vaccinated cohort. This method could be used to retroactively investigate the epidemiology and incremental long-term health consequences of SARS-CoV-2 reinfections.
Keywords: COVID-19; SARS-CoV-2; avidity; nucleocapsid; reinfection; serology.